The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1434
In Brief: Ponatinib (Iclusig) Returns
Download PDF:   US English
 Select a term to see related articles  Iclusig   Leukemia   ponatinib 

The October 2013 suspension of marketing and sales of ponatinib (Iclusig – Ariad) for treatment of leukemia1 has been lifted by the FDA, and the drug is expected to return to the market this month with narrower indications and heightened safety warnings.2 The reason for its suspension was a high incidence of thrombotic events, some of them fatal. The new indications limit use of the drug to patients with T315I-positive disease and those "for whom no other tyrosine kinase inhibitor is indicated," presumably because of resistance or intolerance.

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.